Medical Science Liaison Society - What is an MSL? The Medical Science Liaison (MSL) is a specific role within the pharmaceutical, biotechnology, medical device, CRO and other health-care industries. MSLs have advanced scientific training and academic credentials generally consisting of a doctorate degree (Ph.D., PharmD., M.D.) in the life sciences. They concentrate on a specific Therapeutic Area (i.e. Oncology, Cardiology, CNS, Pulmonary, Hematology, Surgery, Women's Health Care, etc) and disease state. Medical Science Liaisons are vital in the success of a company. They work throughout a product's lifecycle, help to ensure that products are utilized effectively, serve as scientific peers and resources within the medical community, and are scientific experts to internal colleagues at companies.
Twitter awareness/engagement ratio: a pillory or a pedestal for I was riffing with Mike Baldwin yesterday about how social media is impacting upon the dynamics of the relationship between awareness and engagement. Mike has said he will blog about this topic at some point, and I look forward to reading it. Our conversation reminded me of a post by David Bradley on SciScoop last November shortly after the launch of Twitter lists wherein David divided the number of lists leading science tweeters were featured in by their follower count in order to derive a ‘Twitter respect ratio for science’. I thought it would be fun to do something similar for pharma. The Secret Of Successful Social Communities: 4 Social Needs Ever since I first started working with online social communities I've been thinking about just what it is that makes some communities successful while others fizzle and die. In particular I'm curious why collaboration communities seem to be so hard to make work. Of course we have plenty of research into the strategies and tactics involved in setting up and running a successful social community, and we continue to publish new research and insights each month.
Top Ten Drug Companies in Social Media What is the "social share of voice" among pharmaceutical companies online? While some drug companies have been reluctant to embrace social media for fear of running afoul of FDA regulations that govern the advertising and promotion of prescription drugs, others are embracing social networks to help brand and position their companies in a positive light with consumers and practitioners. Here are the TOP TEN Pharma companies that are presently useing social media to reach out to larger audiences. 1- Pfizer Pfizer, maker of the well-known drugs of Viagra and Celebrex, is exploring social media by teaming up with Private Access to create a social networking site. that will bring together patients and clinical trial researchers. Once the site is up and running, patients will have the opportunity to confidentially post personal health information that will only be made available to researchers studying their particular condition.
Eight great location-based mobile campaigns from 2012 Location-based mobile services have been one of the major digital trends this year, as they provide a great opportunity for retailers and brands to create contextual experiences to engage their customers. One of the most obvious uses of location services is providing targeted offers and promotions to smartphone owners in-store. But we’ve also seen brands with little or no retail presence using mobile to add an additional layer of interaction to traditional outdoor advertising. There are a number of great examples of brands using location-based mobile services this year, but here is a run down of eight of my favourite campaigns. If you think I’ve missed any good ones, please point them out in the comments section... Douche Parking
FDA to trawl PatientsLikeMe data to identify drug side effects The FDA entered a research collaboration agreement with online patient network PatientsLikeMe to "determine how patient-reported data can give new insights into drug safety," the parties announced Monday. Under the deal, the agency and PatientsLikeMe will "explore the potential of patient-generated data to inform regulatory review activities related to risk assessment and risk management." Gerald Dal Pan, director of the FDA's Office of Surveillance and Epidemiology, explained that "we're hoping we can find information on the impact of adverse events on patients' day-to-day lives," but it is unclear if the collaboration "will give us the kind of information that will be sufficient to make label changes. That's what we're trying to find out." Dal Pan also noted "there's a lot of interesting app development for reporting adverse events," adding that "we're going to have to explore the value of social media."
Media and Political Marketing- There Is No A presumption common to much of the political news coming out the U.S. these days is that voters have rejected party politics to be "independents," and that these voters represent a vast "middle" from which candidates must draw. Good luck with that. I'd argue that these voters have instead migrated to various extremes, and that the only thing they may share in common is an unredeemable distrust and impatience with government. To characterize the political expectations of these extremists as a "middle" of anything other than chaos is a fantasy invention and easy excuse for cable talk show hosts; I think there's something far deeper going on, and it involves the changing way people (voters or consumers) relate to institutions, whether government or business:
The Social Life of Health Information 61% of American adults look online for health information. In 2000, 46% of American adults had access to the internet, 5% of U.S. households had broadband connections, and 25% of American adults looked online for health information. Now, 74% of American adults go online, 57% of American households have broadband connections, and 61% of adults look online for health information. We use the term “e-patient” to describe this group. Further, “always present” mobile access draws people into conversations about health as much as online tools enable research.